Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease

Phase 2CompletedNCT00465959

Endo USA Inc., a Keenova Therapeutics Company24 enrolled

Overview

To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

trospium chloride inhalation powder (TrIP)DRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female COPD patients between the ages of 40 and 80 years * Smoking history of at least 10 pack years * Not currently using (or able to wash out of) any long acting bronchodilators Exclusion Criteria: * Candidate on a waiting list for surgery while on study * Using long-term oxygen therapy * Hospitalization for COPD exacerbation

Locations (1)

United States Investigational Site

Spartanburg, South Carolina, United States

Outcomes

Primary Outcomes

Safety and efficacy (measured by spirometry) of TrIP will be assessed in patients with chronic obstructive pulmonary disease.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.